Gibson Dunn Advised X4 Pharmaceuticals on Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
X4 Pharmaceuticals received advice from Gibson Dunn about its public offering of common stock and the full exercise of the underwriters’ option to buy additional shares for $155.3 million in gross proceeds.